Moderna’s new mRNA (messenger Ribonucleic Acid) flu shot completed the phase 3 trials with succeeding data. They are aiming to launch in early 2024. The flu vaccine – mRNA-1010 has produced an immune response against all four A and B strains – A/H1N1, A/H3N2, influenza B/Yamagata, and B/Victoria.
“Our mRNA platform is working. With today’s positive Phase 3 flu results, along with previous results in COVID and RSV, we are now three for three on advancing respiratory disease programs to positive Phase 3 data,”
Stéphane Bancel, Chief Executive Officer of Moderna
Moderna could use these positive data to seek approval (accelerated) by the end of 2023. Compared to other brands, Moderna’s flu vaccine exhibited high levels of antibodies in four tested strains.
At the same time, Moderna is reducing its mRNA-based COVID-19 shots as the demand for the vaccine is falling globally.
“We probably overproduced a little bit too much this year, which is why we have excessive unutilized capacity and excessive materials, and that will come down,”
Jamey Mock, CFO Moderna – Reported by Reuters
Source: Moderna, Reuters
Report by: Achuth B S
Published: 14-September-2023
Updated:
